Formerly CB1 Botanicals, CF Biotech is developing small molecule inhibitors, targeting the HSP90 protein complex, chemokines/CXCL10, NLRP3 and immune checkpoint proteins PD-L1/2. Funded by the Irish and Maltese governments (€1.2m) to address unmet clinical needs in ovarian cancer, neurodegenerative disorders and chronic inflammation, CF Biotech's vision is to enter Phase I trials in 2024.